Tellgen(SZ:300642) Sou Hu Cai Jing·2025-08-15 10:14Company Overview - Shanghai TuoJing Life Technology Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic products under its own brand [1] - The main products include in vitro diagnostic reagents, in vitro diagnostic instruments, and service income [1] - The company actively participates in various health-themed public welfare activities and has received multiple awards for social responsibility, including the "Social Public Welfare Award" from the China Cancer Foundation [1] Financial Performance - As of the first quarter of 2025, the company reported operating revenue of 74.89 million yuan, a year-on-year decrease of 19.53% [1] - The net profit for the same period was 471,700 yuan, showing a year-on-year increase of 110.51% [1] - The sales gross margin stood at 63.66% [1] Market Position - The company's stock closed at 20.05 yuan, with a rise of 4.97%, and a rolling price-to-earnings (PE) ratio of 82.52, marking a new low in 494 days [1] - The total market capitalization is 3.259 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 56.58, with a median of 39.97, placing TuoJing Life at the 100th position in the industry ranking [1][2] Institutional Holdings - As of the first quarter of 2025, only one institution holds shares in TuoJing Life, with a total of 18,800 shares valued at 0.00 billion yuan [1]